ANZCTR search results

All patients attending 2 dental practices for oral appliance therapy to treat obstructive sleep apnoea will be assessed for recruitment. Those who are able to sign informed consent will be enrolled. If a polysomnogram (PSG) has not been done, this will be done to confirm the apnoea hypopnoea index (AHI). Participants will be randomised to either usual care or usual care plus an apnealink study to evaluate treatment response. Should treatment response be inadequate as indicated by the ApneaLink in this group, further advancement of the mandible will be attempted. A repeat ApneaLink study will then be done and the process repeated. One month after titration is considered optimal, repeat PSG will be done. A repeat PSG will be done 1 month after optimal titration has been achieved in the control group. Secondary outcome measures of quality of life, symptoms and subjective sleepiness will be measured at baseline and at the time of the repeat PSG in both groups.

The purpose of this research is to compare the effect of the treatments (Tamoxifen and Exemestane) used in the main trial (TEXT-2) on bones. This will provide researchers and doctors with information as to whether these drugs are safe in terms of bone health and if there are increased or decreased risks of osteoporosis with the treatments. Approximately 200 patient's will be enrolled in this sub-study worldwide. Every patient will be in the sub-study for an average period of six years. However, participation in the study could be shorter depending on the response to the treatment on the main study.

Since the inception of human organ transplantation, HCMV remains single most-important cause of infectious morbidity and mortality in immunocompromised transplant patients. This project is designed to develop immunotherapeutic strategies based on adoptive transfer of virus- specific killer T cells for the treatment of HCMV infection in transplant patients. Who is it for? You can join this study if you have had an allogeneic haematopoietic stem cell transplant or a renal transplant at the Royal Brisbane Hospital and have a CMV infection. Trial details Blood will be collected from your stem cell donor (for SCT patients) or yourself and the CMV killer T cells grown in the laboratory (this takes about 3 weeks.) The cells are then tested for sterility and specificity. Once the cells pass these checks they will be infused into yourself: 4 doses at 2 weekly intervals and then a further 2 doses at 4 weekly intervals provided sufficient cells are produced. The effects of the treatment will be studied by monitoring your signs and symptoms and by blood tests. This will be done at the time of each treatment and then monthly for up to a year from the first treatment. Your total length of involvement will be no longer than 18 months.

This study aims to determine whether oxytocin improves emotion perception and understandind in people who have a diagnosis of Schizophrenia

We are examining pain management in those patients who present to the emergency department with a fractured hip. Current practice in St Vincent's hospital emergency department is regular paracetamol and parenteral morphine. The POTENTIAL side effects of morphine are well known particularly in the older age group and include such effects as: drowsiness and/or confusion; nausea and vomiting; clinical significant slowing of breathing and lowering of blood pressure. Particular in those who receive significant amounts of morphine. Our aim is to show that patients who receive an ultrasound guided femoral nerve block AS PART OF their pain control management will require clinically significant less morphine than those who do not. In fact we are hoping to show these patients use 50% less morphine. If this is the case we will be supporting the idea of introducing ultrasound guided femoral nerve blocks to current clinical practice guidelines for managing pain in fractured hips.

This intervention trial is a pragmatic study to investigate the impact of three feeding assistance models on energy intake of older hospitalised patients (compared with pre-intervention data) and will provide some pilot data for other clinical outcomes, such as functional capacity, length of stay and mortality. This study will add to the limited evidence base on interventions to improve nutritional intake in elderly hospital patients. While this study will not be adequately powered to determine whether clinical outcomes are improved with these interventions, findings could be used to inform the design of larger trials to further evaluate outcomes such as functional status, hospital readmission and mortality. This study will also explore the impact of the different feeding assistance models on ward culture. As implementation of these interventions will require complex changes to service delivery, it is imperative that changes in staff behaviours and their perspective and acceptability of interventions are explored.

This study aims to better understand the way in which painful osteoarthritis affects different people and whether an anti-inflammatory medication such as Arcoxia (etoricoxib) can help to modify this pain. The study will use questionnaires and tests of pain sensitivity to identify arthritis sufferers with more widespread, nerve-type pain and then to investigate whether a daily dose of Arcoxia is more effective than a placebo pill in reducing these symptoms and improving functional movements. The study will also be comparing the same test results of a small group of subjects without knee pain.

This is a project being jointly conducted by departments of Anesthesia and Psychiatry at Ballarat Health Services. Anaesthetic agents such as hypnotics tend to increase the seizure threshold in patients undergoing electroconvulsive therapy (ECT). Consequently, higher current strength may be required to induce seizure activity. This study aims to reduce the dose of such anaesthetic agents. However, this does not imply that patients will be awake or partially awake at the time of ECT. Agents that do not increase seizure threshold such as opioids would be used in combination with hypnotics. In fact, a monitor to record depth of anaesthesia, will be employed during this study to ensure patients are asleep before ECT is administered. This study will be approved by Ballarat Health Services and St John of God Human Research and Ethics Committee. The main aim of the study is to determine optimal dose of anesthetic agents used with or without opioid to induce good quality seizure.

The aim of this study was to determine whether a new antipsychotic medication, quetiapine (Seroquel) is a safe and effective treatment for young people with anorexia nervosa